0001448431 2022-01-01 2022-03-31 0001448431 2022-04-29 shares 10-Q/A true 2022-03-31 2022 false 001-38543 OptimizeRx Corporation NV 26-1265381 400 Water Street Suite 200 Rochester MI 48307 Common Stock, par value $0.001 OPRX NASDAQ Yes Yes Large Accelerated Filer false false false 18152349 OptimizeRx Corporation is filing this Amendment No. 1 on Form 10-Q/A (“Amendment No. 1”) to its Quarterly Report on Form 10-Q for the period ended March 31, 2022, originally filed with the Securities and Exchange Commission (SEC) on May 9, 2022 (the “Original 10-Q Filing”) to address management’s re-evaluation of disclosure controls and procedures and to reflect the identification of a material weakness. The material weakness did not result in any change to the Company’s consolidated financial statements as set forth in the Original 10-Q Filing.This Amendment No. 1 is limited in scope to make the following changes to the Original 10-Q Filing: ●To amend Part I - Item 4. Controls and Procedures to reflect management’s (i) re-evaluation of our disclosure controls and procedures, and (ii) identification of a material weakness. ●To amend Part II - Item 6. Exhibits to include the following currently dated documents: certifications from the Company’s Chief Executive Officer and Chief Financial Officer as required by Sections 302 and 906 of the Sarbanes Oxley Act of 2002, which certifications are filed herewith as Exhibits 31.1, 31.2, and 32.1.This Amendment No. 1 has not been updated or amended to give effect to any subsequent events beyond those that existed as of the original filing date and should thus be read in conjunction with the Original 10-Q Filing and any of the company’s other filings with the SEC subsequent to the Original 10-Q Filing, together with any amendments to those filings. Other than the filing of the information identified above, this amendment does not modify or update the disclosure in the Original 10-Q Filing in any way. Unless otherwise specified or the context otherwise requires, when used in this Amendment No. 1, the terms “we,” “our,” “us,” “OptimizeRx,” or the “Company” refer to OptimizeRx Corporation and its subsidiaries.The Company is concurrently filing Amendment No. 1 to each of its (i) Annual Report on Form 10-K for the year ended December 31, 2021 and (ii) Quarterly Reports on Form 10-Q for the quarterly periods ended June 30, 2022 and September 30, 2022. 651-6568 248 true --12-31 Q1 0001448431